Abivax SA Sponsored ADR (NASDAQ:ABVX) Shares Shorted: Short Interest Down 43.3% in October

Abivax logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest fell 43.3% in October to 4.11 million shares, equal to 4.7% of Abivax’s shares; the short-interest ratio was 4.6 days.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $155. Ratings included 13 Buys, one Strong Buy, one Hold, and one Sell.
  • Abivax shares recently traded at $82.78, down 1.0%. The company reported a quarterly loss of $1.71 per share, wider than analysts’ expected $0.92 loss, while revenue exceeded estimates.
  • Five stocks we like better than Abivax.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) saw a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 4,110,784 shares, a decline of 43.3% from the October 15th total of 7,254,941 shares. Currently, 4.7% of the shares of the company are sold short. Based on an average daily volume of 888,647 shares, the short-interest ratio is presently 4.6 days.

Hedge Funds Weigh In On Abivax

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABVX. Versant Capital Management Inc purchased a new stake in Abivax during the 2nd quarter worth about $30,000. Assetmark Inc. boosted its holdings in Abivax by 41.5% in the 1st quarter. Assetmark Inc. now owns 886 shares of the company's stock valued at $99,000 after purchasing an additional 260 shares during the period. Troluce Capital Advisors LLC purchased a new position in shares of Abivax during the 2nd quarter valued at $133,000. Hantz Financial Services Inc. grew its position in shares of Abivax by 22.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,296 shares of the company's stock valued at $128,000 after purchasing an additional 238 shares in the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Abivax by 6.1% in the third quarter. HighTower Advisors LLC now owns 2,125 shares of the company's stock worth $210,000 after purchasing an additional 122 shares during the period. Institutional investors own 47.91% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ABVX shares. Piper Sandler reissued an "overweight" rating on shares of Abivax in a report on Wednesday, October 21st. Barclays reissued an "overweight" rating and set a $148.00 target price on shares of Abivax in a report on Tuesday, September 22nd. Truist Financial cut their price target on shares of Abivax from $155.00 to $151.00 and set a "buy" rating on the stock in a report on Tuesday, September 22nd. Guggenheim reissued a "buy" rating and issued a $175.00 price objective on shares of Abivax in a research note on Tuesday, October 20th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Abivax in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $155.00.

Get Our Latest Stock Analysis on ABVX

Abivax Trading Down 1.0%

Shares of NASDAQ:ABVX traded down $0.83 during mid-day trading on Tuesday, hitting $82.78. 382,232 shares of the company traded hands, compared to its average volume of 1,364,180. The stock has a market cap of $7.25 billion, a P/E ratio of -13.70 and a beta of 1.36. Abivax has a 12-month low of $69.81 and a 12-month high of $148.83. The stock has a 50-day moving average price of $94.22 and a two-hundred day moving average price of $112.38.

Abivax (NASDAQ:ABVX - Get Free Report) last released its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, analysts expect that Abivax will post -4.14 earnings per share for the current year.

Abivax Company Profile

(Get Free Report)

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body's immune response. The company's lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abivax Right Now?

Before you consider Abivax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.

While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines